Many researchers are focusing on various types of tumor proliferation markers, gene mutations/methylations, and histone mutations of GBM, such as Ki-67; TP53 mutations; epidermal growth factor receptor (EGFR) amplification and its mutant EGFRvIII, isocitrate dehydrogenase (IDH) 1/2 mutation; telomerase reverse transcriptase (TERT) promoter mutation; histone H3 mutations; epigenetic modifications of O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation; and 1p19q co-deletion as prognostic markers of malignant glioma [10,11]. This evidence concerns the gene MGMT and malignant glioma.